The University of Iowa
The University of Iowa News Services Home News Releases UI in the News Subscribe to UI News Contact Us

 

CONTACT: TOM MOORE
Joint Office for Planning, Marketing and Communications
8788 John Pappajohn Pavilion
Iowa City IA 52242
(319) 356-3945
e-mail: thomas-moore@uiowa.edu

Release: April 24, 2002

IMPORTANT UPDATE [Posted Oct. 29, 2008] The SELECT study is no longer enrolling participants, and current study participants will no longer take study medication as of Oct. 27, 2008. Current study participants who would like more information may contact either Diane Meyerholz at diane-meyerholz@uiowa.edu or 319-356-1111 or Dr. Richard Williams at 319-356-0760.

UI Health Care cancer prevention seminar for men and women set for May 8

University of Iowa Health Care researchers will hold a free educational seminar about breast and prostate cancer prevention from 6:30 to 8 p.m. Wednesday, May 8 at the Clarion Conference Center, 1220 First Ave., in Coralville.

Adel Al-Jurf, M.D., professor in the UI department of surgery, and Richard Williams, M.D., professor and head of the UI department of urology, will discuss risk factors and prevention strategies for both cancers. Their presentations will be followed by separate overviews of the Study of Tamoxifen and Raloxifene (STAR) Breast Cancer Prevention Study and the SELECT (focusing on the role of selenium and Vitamin E) Prostate Cancer Prevention Study. Both research trials are enrolling participants.

The STAR trial is comparing two medications, tamoxifen and raloxifene, to determine their effectiveness in preventing breast cancer among postmenopausal women age 35 or older who are at risk for the disease. The Food and Drug Administration (FDA) has approved tamoxifen for reducing the rate of invasive breast cancer among women who are at high risk for the disease. Raloxifene is FDA-approved for the prevention of osteoporosis among postmenopausal women. Specialists suggest that raloxifene may have the same ability to prevent breast cancer as tamoxifen, but that premise needs more study. More than 22,000 women are expected to enroll in the STAR research trial.

The SELECT study is a research campaign supported by the National Cancer Institute. Researchers are studying the potential of selenium and vitamin E supplements in preventing prostate cancer. Research centers for SELECT are enrolling men who are more than 55 years old.

To register or for more information, call UI Health Access at (319) 384-8442 or toll-free at (800) 777-8442.

University of Iowa Health Care describes the partnership between the UI Roy J. and Lucille A. Carver College of Medicine and UI Hospitals and Clinics and the patient care, medical education and research programs and services they provide. Visit UI Health Care online at www.uihealthcare.com.